Assistant Professor, Medicine, UCSF School of Medicine
Oncology
Dr. Michelle E. Melisko, MD
|
|
Give Review
Michelle E. Melisko, MD works in the field of Oncology. He researched medicine at Wake Forest School of Medicine. He over the years received 2 awards: "CMS Meaningful Use Stage 1 Certification" and "Super Doctor". Dr. Michelle E. Melisko is a published doctor. He has 35 papers published. The most current publication "Gene Expression Profiling of Evening Fatigue in Women Undergoing Chemotherapy for Breast Cancer." He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Comparison of subgroups of breast Cancer patients on pain and co-occurring symptoms following chemotherapy.
- A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor Malignancies.
- Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast Cancer.
- The Neoadjuvant Model is Still the Future for Drug Development in Breast Cancer.
- Genome-wide copy number Analysis of cerebrospinal fluid tumor cells and their corresponding archival primary tumors.
- SIS.NET: A randomized controlled trial evaluating a web-based system for symptom management after treatment of breast Cancer.
- Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy.
- Association between an interleukin 1 receptor, type I promoter polymorphism and self-reported attentional function in women with breast Cancer.
- Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast Cancer patients with leptomeningeal carcinomatosis.
- A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast Cancer.
- Provider perceptions and expectations of breast Cancer posttreatment care: a University of California Athena Breast Health Network project.
- Clinical trial discussion, referral, and recruitment: physician, patient, and System factors.
- Survivorship Clinic Group Educational Sessions: Adoption, Acceptance, and Attendance.
- Differences in sleep disturbance, fatigue and energy levels between women with and without breast pain prior to breast Cancer surgery.
- The impact of an electronic health questionnaire on symptom management and behavior reporting for breast Cancer survivors.
- Patient perceptions of reproductive health counseling at the time of Cancer diagnosis: a qualitative study of female California Cancer survivors.
- Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with Cancer.
- Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for Cancer.
- Amelioration of sexual adverse effects in the early breast Cancer patient.
- A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic Tumors that express HER-2/neu.
- Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity...
- Patient and physician attitudes toward breast Cancer clinical trials: developing interventions based on understanding barriers.
- Reactivation of hepatitis C virus after chemotherapy for colon Cancer.
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast Cancer.
- Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment.
- Case report: painful peripheral neuropathy following treatment with docetaxel for breast Cancer.
- Phase I trial and antitumor effects of BZL101 for patients with advanced breast Cancer.
- A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast Cancer.
- Long-term prognostic role of functional limitations among women with breast Cancer.
- A changing perspective: improving access to fertility preservation.
- Brain metastases of breast Cancer.
- New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast Cancer.
- Brain metastases in breast Cancer: clinical and pathologic characteristics associated with improvements in survival.
- Gene Expression Profiling of Evening Fatigue in Women Undergoing Chemotherapy for Breast Cancer.
Schools
Wake Forest University
Stanford Hospital
Procedures Preformed
- Thoracentesis
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Basic HMO
- Choice Plus POS II
- Vitalidad Plus California Con Aetna
- Blue Card PPO
- CaliforniaCare HMO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Pathway X Direct Access PPO
- Pathway X Tiered Direct Access
- Select Plus HMO
- Select PPO
- Access Plus Savenet
- Enhanced Exclusive for Small Business HMO
- Local Access Plus HMO
- Brown & Toland Physicians
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- Delta Health System
- Emblem Health
- First Health (Coventry Health Care) PPO
- Blue & Gold HMO
- Covered California - Bronze PPO
- Employer Group HMO
- Health Net PPO
- Individual and Family PPO
- WholeCare Network HMO
- HealthSmart
- Medical Mutual of Ohio
- Medicare MCR
- Kaiser PHCS Network PPO
- MultiPlan PPO
- PHCS Network PPO
- Principal Life
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- PacifiCare HMO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
UCSF -
Stanford University -
Wake Forest School of Medicine
Hospital
-
San Francisco General Hospital and Trauma Center -
UCSF Medical Center
Drug Facts
| NPI NUMBER | 1306803812 | |
| NPPES Provider LastName | MELISKO | |
| NPPES Provider FirstName | MICHELLE | |
| NPPES Provider ZIPCode | 941430001 | |
| NPPES Provider State | CA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 591.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 26.0 | |
| Percent Opioid Claims | 4.4 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1306803812 |
| Last Name Of The Provider | MELISKO |
| First Name Of The Provider | MICHELLE |
| View All |
Similar Doctors
|
|
Dr. Jeffrey L. Wolf, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark M. Moasser, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Usha K. Sunkara, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew C. Hsieh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Derek Kerr, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael R. Burgess, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Frank A. Scappaticci, MD
This Doctor is OpenDoctor Recommended.
|